AbbVie Q2 GAAP EPS climbs 290.4% to $2.03; net revenues rise 10.2% to $16.99 billion vs Q2 FY25

• AbbVie posted second-quarter GAAP EPS of $2.03, up 290.4% from a year earlier; non-GAAP adjusted EPS rose 22.9% to $3.65.
• Net revenues increased 10.2% from a year earlier to $16.99 billion, led by immunology revenue up 15.1% to $8.79 billion.
• Skyrizi net revenues climbed 24.4% to $5.51 billion; Rinvoq net revenues rose 24.5% to $2.53 billion.
• Neuroscience net revenues grew 20.3% to $3.23 billion; oncology net revenues slipped 1.5% to $1.65 billion.
• Guidance for 2026 non-GAAP adjusted EPS narrowed to $13.87-$14.07, including a $0.14 per-share dilutive impact from the planned Apogee acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607310747PR_NEWS_USPR_____CG16376) on July 31, 2026, and is solely responsible for the information contained therein.